Mark Geyer: Tigen Pharma has formally agreed to partner with us in clinical development of our CAR T-cell product for AML

Mark Geyer: Tigen Pharma has formally agreed to partner with us in clinical development of our CAR T-cell product for AML

Mark Geyer, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center, recently shared on X/Twitter:

“Thrilled that Tigen Pharma has formally agreed to partner with us in clinical development of our CD371-targeted IL-18 secreting CAR T-cell product for AML, currently in a phase I study I’m leading at Memorial Sloan Kettering Cancer Center with plans to expand.”

Read further.

Source: Mark Geyer/X

AML cancer CAR T-CELL IL-18 Mark Geyer OncoDaily Oncology Research Tigen Pharma